Jennifer L Medlin1, Karen E Hansen2, Sara S McCoy2, Christie M Bartels3. 1. University of Wisconsin Hospital and Clinics, Madison, WI. 2. Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Rm 4132, Madison, WI. 3. Department of Medicine, Rheumatology Division, University of Wisconsin School of Medicine and Public Health, 1685 Highland Ave, Rm 4132, Madison, WI. Electronic address: cb4@medicine.wisc.edu.
Abstract
OBJECTIVES: Phenotypes differ between late- and early-onset systemic lupus erythematosus (SLE). Prior studies suggested that there may be more pulmonary disease among late-onset patients. Our objective was to perform a systematic review and meta-analysis to evaluate the differences in pulmonary manifestations in late- versus early-onset SLE. METHODS: We searched the literature using PubMed, CINAHL, Web of Science, Cochrane Library, and EMBASE. We excluded studies that did not include American College of Rheumatology SLE classification criteria, an early-onset SLE comparison group, or those that defined late-onset SLE as <50 years of age. We rated study quality using the Newcastle-Ottawa Quality Scale. We used Forest plots to compare odds ratios (95% confidence intervals) of pulmonary manifestations by age. Study heterogeneity was assessed using I2. RESULTS: Thirty-nine studies, representing 10,963 early-onset and 1656 late-onset patients with SLE, met eligibility criteria. The odds of developing several pulmonary manifestations were higher in the late-onset group. Interstitial lung disease (ILD) was nearly three times more common (OR = 2.56 (1.27, 5.16)). Pleuritis (OR = 1.53 (1.19, 1.96)) and serositis (OR = 1.31 (1.05, 1.65)) were also more common in the late-onset group. The mean Newcastle-Ottawa Quality Scale score for study quality was moderate (6.3 ± 0.7, scale 0-9). CONCLUSIONS: Pulmonary manifestations of SLE were more common in late-onset SLE patients compared to their younger peers, in particular ILD and serositis. Age-related changes of the immune system, tobacco exposure, race, and possible overlap with Sjögren's syndrome should be examined in future studies.
OBJECTIVES: Phenotypes differ between late- and early-onset systemic lupus erythematosus (SLE). Prior studies suggested that there may be more pulmonary disease among late-onset patients. Our objective was to perform a systematic review and meta-analysis to evaluate the differences in pulmonary manifestations in late- versus early-onset SLE. METHODS: We searched the literature using PubMed, CINAHL, Web of Science, Cochrane Library, and EMBASE. We excluded studies that did not include American College of Rheumatology SLE classification criteria, an early-onset SLE comparison group, or those that defined late-onset SLE as <50 years of age. We rated study quality using the Newcastle-Ottawa Quality Scale. We used Forest plots to compare odds ratios (95% confidence intervals) of pulmonary manifestations by age. Study heterogeneity was assessed using I2. RESULTS: Thirty-nine studies, representing 10,963 early-onset and 1656 late-onset patients with SLE, met eligibility criteria. The odds of developing several pulmonary manifestations were higher in the late-onset group. Interstitial lung disease (ILD) was nearly three times more common (OR = 2.56 (1.27, 5.16)). Pleuritis (OR = 1.53 (1.19, 1.96)) and serositis (OR = 1.31 (1.05, 1.65)) were also more common in the late-onset group. The mean Newcastle-Ottawa Quality Scale score for study quality was moderate (6.3 ± 0.7, scale 0-9). CONCLUSIONS: Pulmonary manifestations of SLE were more common in late-onset SLEpatients compared to their younger peers, in particular ILD and serositis. Age-related changes of the immune system, tobacco exposure, race, and possible overlap with Sjögren's syndrome should be examined in future studies.
Authors: S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg Journal: Clin Rheumatol Date: 1998 Impact factor: 2.980
Authors: G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: J H Choi; D J Park; J H Kang; Y R Yim; K E Lee; J W Lee; L Wen; T J Kim; Y W Park; J K Lee; S S Lee Journal: Lupus Date: 2015-06-17 Impact factor: 2.911
Authors: J Thumboo; K Uramoto; W M O'Fallon; K Y Fong; M L Boey; P H Feng; S T Thio; S E Gabriel; H H Chng; H S Howe; E T Koh; W H Koh; K H Leong; K P Leong Journal: Arthritis Rheum Date: 2001-12
Authors: M C Hochberg; R E Boyd; J M Ahearn; F C Arnett; W B Bias; T T Provost; M B Stevens Journal: Medicine (Baltimore) Date: 1985-09 Impact factor: 1.889
Authors: Natalia Mena-Vázquez; Antonio Fernández-Nebro; José María Pego-Reigosa; María Galindo; Ana Melissa-Anzola; Esther Uriarte-Isacelay; Alejandro Olivé-Marqués; Elena Aurrecoechea; Mercedes Freire; Eva Tomero; María Jesús García-Villanueva; Claudia Stoye; Esteban Salas-Heredia; Jose Antonio Bernal-Vidal; Eva Salgado; Ricardo Blanco; Francisco Javier Novoa; Mónica Ibáñez-Barcelo; Vicente Torrente-Segarra; Javier Narvaez; Joan Calvet; Clara Moriano Morales; Tomas Ramon Vazquez-Rodriguez; Paloma Garcia de la Peña; Cristina Bohórquez; José Luis Andreu-Sánchez; Tatiana Cobo-Ibañez; Gema Bonilla; Nuria Lozano-Rivas; Carlos Montilla; Francisco Javier Toyos; Jose Luis Marenco De la Fuente; Lorena Expósito; María Esther Ruiz-Lucea; Elia Vals; Javier Manero-Ruiz; Jose A Bernal-Vidal; Iñigo Rua-Figueroa Journal: Rheumatology (Oxford) Date: 2020-08-01 Impact factor: 7.580
Authors: Gerwyn Morris; Eugene Athan; Ken Walder; Chiara C Bortolasci; Adrienne O'Neil; Wolf Marx; Michael Berk; André F Carvalho; Michael Maes; Basant K Puri Journal: Life Sci Date: 2020-10-06 Impact factor: 6.780